| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Rare Diseases |
Recent Updates
Recently added Catalysts
Pharvaris N.V.$35.07
-0.89 (-2.47%)
C 47Pipeline Score Overvalued Biotech · Clinical
Market Cap
1.94 B
EPS
-3.18
P/E Ratio
-
Value Trade
20.96 M
-2.18 %
Week
0.37 %
1 Month
5.7 %
3 Month
22.44 %
6 Month
33.64 %
5 Year
18.72 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
639.30 K
52 Week Range
15.46 - 33.33
% held by Insiders
53.13 %
% held by Institutions
40.1 %
Enterprise Value
1.66 B
Total Shares
65.43 M
Short %
2.83 %
Float Shares
34.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pharvaris N.V.
359Total events
8Upcoming
56Tier-1 (high impact)
2021 – 2027Coverage
Upcoming catalysts 8
TBD
T1NDA Submission
Preparing marketing authorization applications for deucrictibant immediate-release capsule as on-demand treatment of HAE attacks
2026-H1
T1NDA Submission
NDA submission of deucrictibant IR for on-demand treatment of HAE attacks anticipated
TBD
T3Poster Presentation
Additional efficacy, safety, and patient experience data to be presented at upcoming medical congresses
Event history 351
Jul 6, 2026
▲FDA Filing AcceptedDeucrictibantRegulatory Filing
FDA accepts NDA for deucrictibant IR for on-demand treatment of HAE attacks
Hereditary Angioedema (HAE)source ↗
Jul 6, 2026
▲Primary Endpoint MetDeucrictibantClinical Data
RAPIDe-3 met primary and all 11 secondary endpoints with statistical significance
Hereditary Angioedema (HAE) attackssource ↗
Q3 2026
◆Topline ReadoutDeucrictibantClinical Data
Topline data from CHAPTER-3 (prophylaxis) anticipated
hereditary angioedema (HAE)source ↗
Q3 2026
◆Topline ReadoutDeucrictibantClinical Data
Topline data anticipated for CHAPTER-3 Phase 3 study of deucrictibant extended-release tablet for prevention of HAE attacks
hereditary angioedema (HAE) attacks preventionsource ↗
Q3 2026
◆Topline ReadoutDeucrictibantClinical Data
Topline data from CHAPTER-3 anticipated
hereditary angioedema (HAE)source ↗
Jun 13, 2026
◆Poster PresentationDeucrictibantPresentation
RAPIDe-3 Patient Voices: Qualitative Insights from the Phase 3 Study of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
hereditary angioedemasource ↗
Jun 13, 2026
◆Oral PresentationDeucrictibantPresentation
CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema
hereditary angioedemasource ↗
Jun 12, 2026
▲Oral PresentationDeucrictibantPresentation
Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial
hereditary angioedemasource ↗
Jun 12, 2026
▲Poster PresentationDeucrictibantPresentation
CHAPTER-1 Open-Label Extension Study: Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema
hereditary angioedemasource ↗
Jun 12, 2026
●Poster PresentationPresentation
A Clinically Validated Kinin Biomarker Assay to Differentiate Bradykinin-Mediated from Mast Cell-Mediated Angioedema
bradykinin-mediated angioedemasource ↗
Drug Pipeline Intelligence
C47
Pipeline Score $463M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.2x
rNPV / MCap Top 70%
Micro Cap (rank 274 of 911)
Percentile RankPharvaris N.V. carries a moderate pipeline score (47/100), with $1.2B risk-adjusted pipeline value, led by Deucrictibant in Hereditary Angioedema (HAE) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deucrictibant Small molecule | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | Phase 3 | NCT07266805 | 68% | $988M | RECRUITING | 32 | SLOW | B (67) | Jun 1, 2027 | LOW_RISK | LOW Jun 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
deucrictibant Orphan | hereditary angioedema | Phase 3 | 2026-06-15 | median time to onset symptom relief: 1.28 hours; median time to complete resolution: 11.95 hours; percentage single capsule: 83.0%; percentage no rescue medication: 93.2% Read More | Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 Read More | |
deucrictibant Orphan | hereditary angioedema | Phase 3 | 2026-06-15 | median time to onset symptom relief: 1.28 hours; median time to complete resolution: 11.95 hours; percentage single capsule: 83.0%; percentage no rescue medication: 93.2% Read More | Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 Read More | |
deucrictibant Orphan | hereditary angioedema | Phase 3 | 2026-06-15 | median time to onset symptom relief: 1.28 hours; median time to complete resolution: 11.95 hours; percentage single capsule: 83.0%; percentage no rescue medication: 93.2% Read More | Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PHVS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PHVS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PHVSPharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Pharvaris announced that the FDA has accepted its New Drug Application for deucrictibant IR, an oral treatment for hereditary angioedema (HAE) attacks. The NDA includes positive clinical data showing rapid symptom relief and a favorable safety profile. The FDA has set a PDUFA action date for April 23, 2027. If approved, deucrictibant IR will be the first oral bradykinin B2 receptor antagonist for HAE.
Read more →PHVSData Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Pharvaris presented data on deucrictibant at the EAACI Annual Congress 2026, highlighting its differentiated profile for managing hereditary angioedema (HAE). The Phase 3 RAPIDe-3 study showed rapid symptom relief and high efficacy with a single capsule. The drug also demonstrated a favorable cardiovascular safety profile, supporting its potential as a new standard of care.
Read more →PHVSPharvaris Announces Annual General Meeting of Shareholders
Pharvaris has announced its annual general meeting of shareholders scheduled for June 26, 2026. The meeting will provide shareholders with relevant documents and information, which can be accessed on the company's website and the SEC's site. Pharvaris is focused on developing oral therapies for bradykinin-mediated diseases, with ongoing Phase 3 studies for its treatment candidates.
Read more →PHVSPharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Pharvaris (Nasdaq: PHVS) will present clinical data at the EAACI Annual Congress 2026, showcasing its research on oral bradykinin B2 receptor antagonists for treating hereditary angioedema. The company has one oral presentation and seven abstracts for flash talks/posters scheduled during the event. Notable presentations include results from the Phase 3 RAPIDe-3 trial and insights from the CHAPTER-1 study.
Read more →PHVS▲ +5.4%on this news
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Pharvaris has announced its financial results for Q1 2026, highlighting a successful capital raise and ongoing clinical programs. The company is preparing for the potential launch of deucrictibant, a novel treatment for bradykinin-mediated diseases. Upcoming data from the CHAPTER-3 trial is anticipated in Q3 2026, supporting their strategic focus on these late-stage programs.
Read more →PHVSPharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Pharvaris N.V. has successfully closed an underwritten offering of 4,455,863 ordinary shares, raising approximately $132.3 million. The offering included the full exercise of an option by underwriters to purchase additional shares. The funds will support Pharvaris's development of oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases. The company is preparing for marketing applications and has ongoing Phase 3 studies.
Read more →PHVSPharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
Pharvaris N.V. has priced an underwritten offering of 3,874,664 ordinary shares at $29.68 each, aiming to raise approximately $115 million. The offering, which is expected to close on May 11, 2026, will fund the company's ongoing clinical development of bradykinin B2 receptor antagonists for treating hereditary angioedema and acquired angioedema. The underwriters have an option to purchase additional shares, enhancing the offering's potential.
Read more →PHVSEvidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
Pharvaris presented data at the CIIC Spring 2026 Conference supporting the combined use of deucrictibant immediate-release (IR) and extended-release (XR) formulations for treating bradykinin-mediated diseases. The analysis indicated adequate safety margins for this combination, while a post-hoc analysis suggested potential efficacy in managing breakthrough attacks. The company is advancing its clinical development of deucrictibant, aiming to improve treatment options for patients.
Read more →PHVSPharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Pharvaris reported its financial results for Q4 and full year 2025, highlighting the completion of enrollment in the pivotal CHAPTER-3 study for deucrictibant XR. The company remains on track for the NDA submission of deucrictibant IR in 1H2026. Financially, Pharvaris holds €292 million in cash, although it reported a significant annual loss.
Read more →PHVSEvidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
Pharvaris announced the publication of two Phase 2 studies in The Lancet Haematology, demonstrating the efficacy and safety of deucrictibant for treating hereditary angioedema (HAE). The CHAPTER-1 study showed significant reduction in attack occurrences, while RAPIDe-1 indicated effective symptom relief. Both studies support deucrictibant's potential as a novel oral therapy for HAE management.
Read more →PHVSDeucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
Pharvaris presented positive data on deucrictibant at the AAAAI 2026 Annual Meeting, highlighting its efficacy in treating hereditary angioedema (HAE) attacks. The Phase 3 RAPIDe-3 study demonstrated rapid symptom relief and significant improvements in patient outcomes. Additionally, long-term safety data from the CHAPTER-1 study support its use as a prophylactic treatment.
Read more →PHVSPharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting
Pharvaris announced the acceptance of six abstracts for poster presentations at the AAAAI 2026 Annual Meeting. This includes positive results from the RAPIDe-3 study and final data from the Phase 2 CHAPTER-1 study on deucrictibant for hereditary angioedema. The presentations will showcase significant findings and further support the ongoing Phase 3 study of deucrictibant.
Read more →PHVSPharvaris Outlines 2026 Strategic Priorities • Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026 • Preparation of NDA dossier of
Pharvaris has announced its strategic priorities for 2026, focusing on the development of deucrictibant for treating hereditary angioedema (HAE). The company anticipates topline data from the pivotal CHAPTER-3 study in Q3 2026, alongside ongoing preparation for an NDA submission in H1 2026. Recent results from Phase 3 studies have shown positive outcomes for deucrictibant, supporting its potential as a new standard of care for on-demand HAE treatment. Additionally, recruitment for another pivotal study assessing AAE-C1INH treatment is progressing well.
Read more →PHVSPharvaris Outlines 2026 Strategic Priorities
Pharvaris has outlined its strategic priorities for 2026, focusing on the clinical development of deucrictibant, a treatment for hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The company anticipates filing a New Drug Application for deucrictibant's on-demand treatment of HAE attacks in the first half of 2026 and expects topline data from the pivotal CHAPTER-3 study by the third quarter of 2026. Additionally, Pharvaris has reported a cash runway projected into the first half of 2027, supporting ongoing clinical programs.
Read more →PHVS▲ +21.7%on this news
Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks Primary endpoint met; median time to onset of symptom relief achieved in
Pharvaris has announced positive topline data from its RAPIDe-3 pivotal study, demonstrating that the oral bradykinin B2 receptor antagonist, deucrictibant, is effective for the on-demand treatment of hereditary angioedema (HAE) attacks. The study, involving 134 participants across 24 countries, achieved statistical significance across all primary and secondary endpoints. The results support Pharvaris' plans to file for marketing authorization in 2026, highlighting the potential of deucrictibant to provide fast and effective relief for patients experiencing HAE attacks. The findings further reinforce the importance of addressing unmet medical needs in managing bradykinin-mediated diseases.
Read more →PHVS▲ +7%on this news
Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update
Pharvaris reported its third quarter 2025 financial results, highlighting its progress in developing deucrictibant, an oral bradykinin B2 receptor antagonist. The company is set to release data from its pivotal Phase 3 trial, RAPIDe-3, in the fourth quarter of 2025. With financing secured through 2027, Pharvaris continues to advance its pipeline for treating bradykinin-mediated diseases.
Read more →PHVSData Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting
Pharvaris presented data at the ACAAI 2025 Annual Meeting highlighting the efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist for hereditary angioedema (HAE). The findings from multiple studies indicate a significant reduction in HAE attack rates and improvements in patients' quality of life. The company anticipates further data from ongoing Phase 3 trials in 2026.
Read more →PHVSPharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Pharvaris has announced the acceptance of two abstracts for oral presentation and six for poster presentation at the ACAAI 2025 Annual Scientific Meeting. The event will take place from November 6-10 in Orlando, Florida. Pharvaris is focused on developing oral bradykinin B2 receptor antagonists to treat bradykinin-mediated diseases, with ongoing Phase 3 studies for hereditary angioedema.
Read more →PHVSExecution Version] PHARVARIS N.V. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this " Agreemen t") is made as of
Pharvaris N.V. has entered into a Registration Rights Agreement with General Atlantic PH B.V. This agreement outlines the procedures for the registration and sale of securities by the Investor, including the filing of a shelf registration statement. The company will endeavor to keep this registration effective for three years, allowing the Investor to sell shares as desired. Specific conditions under which the company can suspend this registration process are also elaborated, focusing on potential adverse effects on the company's operations.
Read more →PHVSPharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update • Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in
Pharvaris reported its financial results for the second quarter of 2025, highlighting progress in its clinical pipeline and financial position. The company anticipates topline results from its pivotal Phase 3 study, RAPIDe-3, by Q4 2025, which is seen as a critical milestone. Enrollment in another pivotal Phase 3 study, CHAPTER-3, is ongoing, with topline results expected by the second half of 2026. The company's financials show a cash position of $200 million following a successful public offering, though they also incurred significant losses compared to the previous year.
Read more →PHVSPharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Pharvaris N.V. has completed a $201.2 million upsized public offering of ordinary shares and pre-funded warrants. The offering included 9,562,500 ordinary shares, with underwriters fully exercising their option to purchase additional shares. The proceeds will be used to advance the company's development of oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases.
Read more →PHVS▼ -9.9%on this newsshared move
Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
Pharvaris N.V. has announced the pricing of an upsized public offering of $175 million, consisting of 8,250,000 ordinary shares priced at $20.00 each and pre-funded warrants for 500,000 shares. The offering is expected to close on July 24, 2025, pending customary conditions. The funds will support the company's late-stage development of treatments for bradykinin-mediated diseases.
Read more →PHVS▼ -9.9%on this newsshared move
Pharvaris Announces Proposed Public Offering of Ordinary Shares
Pharvaris N.V. announced a proposed public offering of $150 million in ordinary shares to fund research and development, hiring, and general corporate purposes. The offering, which may include an additional $22.5 million option for underwriters, is subject to market conditions. Pharvaris is advancing its late-stage clinical programs for bradykinin-mediated diseases.
Read more →PHVS▲ +7.2%on this news· ran to +36% by day 1
Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Pharvaris has updated the timeline for announcing topline data from its pivotal Phase 3 RAPIDe-3 study of deucrictibant, now expected in Q4 2025. The study aims to evaluate the efficacy of deucrictibant in treating hereditary angioedema (HAE) attacks. If results are positive, Pharvaris plans to submit a New Drug Application to the FDA in early 2026.
Read more →PHVS▼ -5%on this news
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
Pharvaris has announced that abstracts highlighting the clinical trial data for deucrictibant will be presented at the 2025 US HAEA National Summit in Baltimore. The company is focused on developing oral bradykinin B2 receptor antagonists for treating hereditary angioedema. Positive results from Phase 2 studies have led to ongoing pivotal Phase 3 trials for both prevention and on-demand treatment of HAE attacks.
Read more →PHVSPharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress
Pharvaris presented promising data on deucrictibant at the EAACI Congress 2025, highlighting its effectiveness in preventing and treating bradykinin-mediated angioedema attacks. The data from the CHAPTER-1 study indicated sustained attack reduction and improved quality of life for patients. Additionally, the ongoing RAPIDe-3 study aims to explore new endpoints for assessing treatment impact.
Read more →PHVSPharvaris Announces Annual Meeting of Shareholders Zug, Switzerland
Pharvaris has announced the date for its annual general meeting of shareholders, scheduled for June 27, 2025. The company is focused on developing oral bradykinin B2 receptor antagonists for conditions like hereditary angioedema. Pharvaris is currently conducting pivotal Phase 3 studies aimed at both preventing and treating HAE attacks, following successful Phase 2 trials. Shareholders can find further information on the company's website and are encouraged to register for the meeting.
Read more →PHVSPharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Pharvaris presented encouraging data at the 14th C1-Inhibitor Deficiency Workshop regarding their oral bradykinin B2 receptor antagonist, deucrictibant, in treating hereditary angioedema (HAE). The data highlighted its effectiveness in providing durable relief from HAE attacks and potential advantages in both preventive and on-demand treatment scenarios. Participants in clinical studies reported significant improvements in their quality of life and overall satisfaction with the treatment. The company continues to advance its clinical program, with pivotal data expected in the next 18 months.
Read more →PHVSPharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
Pharvaris announced that abstracts for the presentation of clinical data related to deucrictibant have been accepted at three upcoming congresses, including the C1-Inhibitor Deficiency and Angioedema Workshop and the EAACI Congress 2025. Presentations will cover various aspects of the drug's efficacy and safety in treating hereditary angioedema and other related conditions. This highlights Pharvaris's commitment to addressing unmet medical needs in angioedema therapy and underscores the significance of their ongoing clinical research.
Read more →PHVSPharvaris Reports First Quarter 2025 Financial Results and Provides Business Update • Enrollment underway in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline data expecte
Pharvaris reported its financial results for Q1 2025 alongside a business update. The company is currently conducting two pivotal Phase 3 studies, CHAPTER-3 and RAPIDe-3, for its drug deucrictibant, focusing on hereditary angioedema (HAE). Positive developments include receiving TQT study waivers from the FDA and planned forthcoming data releases. However, the company also reported significant financial losses and a decrease in available cash.
Read more →PHVSPharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
Pharvaris plans to host a virtual R&D call titled "Deucrictibant: Beyond HAE Type 1/2" on June 4, at 8 a.m. ET. The event will cover the pathophysiology and treatment needs for bradykinin-mediated angioedema, highlighting the potential of deucrictibant. The company aims to offer innovative treatment solutions with the convenience of oral therapy. Pharvaris is currently in pivotal Phase 3 studies for both prevention and treatment of HAE attacks following promising Phase 2 results.
Read more →PHVS▼ -7.5%on this news
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update • Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of
Pharvaris reported its financial results for 2024 and provided a business update on its development of deucrictibant. The company achieved target enrollment in its pivotal Phase 3 RAPIDe-3 study, aimed at the on-demand treatment of hereditary angioedema (HAE). Additionally, deucrictibant received orphan designation in Europe for treating bradykinin-mediated angioedema, and new data reinforced its efficacy. However, the company recorded a significant financial loss for the year, coupled with rising R&D expenses, while topline data from the CHAPTER-3 study is anticipated in 2026.
Read more →PHVS▼ -5.5%on this news
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
Pharvaris has announced that the European Commission has granted orphan designation to its investigational drug, deucrictibant, which is aimed at treating bradykinin-mediated angioedema. This follows a similar designation by the FDA in March 2022. The company is currently executing a phase 3 clinical development program for deucrictibant to evaluate its efficacy and safety, with promising prior data supporting its potential use in treating hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Pharvaris is developing two formulations of the drug to optimize treatment for patients.
Read more →PHVSPharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025
Pharvaris, a late-stage biopharmaceutical firm, will participate in the 2025 Leerink Partners Global Healthcare Conference in Miami. CEO Berndt Modig is scheduled for a fireside chat on March 10, discussing the company's development of oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases such as hereditary angioedema. Pharvaris aims to provide effective and tolerable oral treatments, with ongoing Phase 3 studies evaluating its lead candidate's efficacy. A live audio webcast will be available for interested investors.
Read more →PHVSPharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Pharvaris presented promising long-term clinical data for deucrictibant at the 2025 AAAAI/WAO Joint Congress, demonstrating its effectiveness in reducing HAE attack rates and improving patients' quality of life. Participants in the CHAPTER-1 open-label extension study experienced a median of zero days with symptoms after long-term treatment. Ongoing studies also indicate that deucrictibant is generally well tolerated, reinforcing its potential as a therapeutic option for hereditary angioedema. The company continues to evaluate deucrictibant’s safety and efficacy in pivotal Phase 3 trials.
Read more →PHVS▼ -7.8%on this news
Pharvaris Outlines 2025 Strategic Priorities • Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema (HAE) attacks in 2024; topline data anticipated in 2H202
Pharvaris has outlined its strategic priorities for 2025, highlighting the initiation of the pivotal CHAPTER-3 Phase 3 study for deucrictibant aimed at preventing hereditary angioedema (HAE) attacks. The company anticipates topline data from this study in 2H2026, along with additional ongoing studies for on-demand treatment and expansion into acquired angioedema due to C1-INH deficiency. Pharvaris maintains a solid financial position, with plans for commercialization pending regulatory approval. The company continues to focus on addressing unmet medical needs within the bradykinin-mediated disease space.
Read more →PHVS▼ -7.8%on this news
Pharvaris Outlines 2025 Strategic Priorities
Pharvaris has outlined its strategic priorities for 2025, focusing on the clinical development of deucrictibant for hereditary angioedema (HAE) and acquired angioedema (AAE). The company has initiated a pivotal Phase 3 study for prophylactic treatment and is progressing with another Phase 3 study for on-demand treatment of HAE attacks, with data releases expected in 2026. Pharvaris is well-positioned financially, with plans to expand its team to support the launch of deucrictibant and address unmet needs in angioedema treatments.
Read more →PHVSPharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates • Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and tre
Pharvaris reported its third quarter financial results and recent business updates, highlighting positive long-term extension data for deucrictibant in the treatment of hereditary angioedema (HAE). The company is preparing to initiate its CHAPTER-3 pivotal Phase 3 clinical study for deucrictibant's prophylactic use by the end of 2024. Despite a notable cash position of $305 million, Pharvaris reported an increase in operational losses year-over-year. Overall, the data reinforces the potential of deucrictibant to meet unmet treatment needs in HAE management.
Read more →PHVS▼ -6.6%on this newsshared move
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
Pharvaris, a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE), announced its participation in the inaugural Guggenheim Healthcare Innovation Conference from November 11-13, 2024. The company's management will take part in a fireside chat on November 13 at 9:30 a.m. ET. Pharvaris boasts positive data from Phase 2 studies and is currently enrolling patients for a pivotal Phase 3 study aimed at on-demand treatment of HAE attacks, with further plans for prevention studies by year-end 2024.
Read more →PHVSPharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Pharvaris presented promising clinical and non-clinical data for deucrictibant at the ACAAI Annual Scientific Meeting. The data, including Phase 2 results, showed significant efficacy in reducing hereditary angioedema (HAE) attacks and supports the drug's development as a prophylactic therapy. The company is currently advancing toward pivotal Phase 3 studies for both on-demand and preventive treatment options. Additionally, they expressed confidence in their regulatory and clinical study designs, bolstered by positive nonclinical outcomes.
Read more →PHVSPharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
Pharvaris, a biopharmaceutical company, has announced the acceptance of multiple abstracts for presentation at several upcoming scientific meetings, highlighting their product Deucrictibant for treating hereditary angioedema (HAE). The presentations will detail the long-term safety, efficacy, and treatment outcomes associated with Deucrictibant. Key presentations will occur at the American College of Allergy, Asthma, & Immunology meeting, Canadian Society of Allergy and Clinical Immunology conference, and the Japanese Society of Allergology event. The company also is advancing a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate another pivotal study for prevention. This signifies a promising step forward in HAE treatment development.
Read more →PHVSPharvaris to Host Virtual Investor Event on October 23, 2024
Pharvaris (Nasdaq: PHVS) will host a virtual investor event on October 23, 2024, to discuss the unmet needs in treating hereditary angioedema (HAE) and the potential of their drug deucrictibant. Presenters will include leading medical experts and Pharvaris executives. The event will feature a Q&A session and will be accessible as an archived replay for 30 days post-event. The company is actively enrolling in Phase 3 studies for on-demand HAE treatment and plans to initiate another study for the prevention of attacks soon.
Read more →PHVSPharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop
Pharvaris has announced the acceptance of six abstracts for presentation at the 2024 HAEi Global Leadership Workshop in Copenhagen. These abstracts will highlight the safety and efficacy of deucrictibant, a bradykinin B2 receptor antagonist aimed at preventing and treating hereditary angioedema (HAE) attacks. The sessions will feature both oral and poster presentations, scheduled for October 4-5, 2024. In addition to showcasing clinical data, Pharvaris plans to donate to the Marcus Maurer Fellowship Program in memory of a key figure in the field.
Read more →PHVS▼ -7.5%on this news
Amendment 2 to the License Agreement entered into by AnalytiCon Discovery GmbH and Pharvaris NV on 31 st March 2016, This Amendment 2 is made between Pharvaris Netherlands BV Emmy Noetherweg 2, 2333 BK Leiden, The Nether
Pharvaris NV and BRAIN Biotech have signed Amendment 2 to a License Agreement originally dated March 31, 2016. This amendment clarifies terms regarding the payment obligations connected to Royalty-Bearing Products, including several specific compounds like deucrictibant (PHVS121). Additionally, the agreement involves the transfer of rights related to revenue from Pharvaris to Royalty Pharma Investments. The amendment is set to take effect upon execution of a related Consent Letter.
Read more →PHVS▲ +10.3%on this news· ran to +24% by day 3
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024
Pharvaris has presented long-term extension data for deucrictibant, indicating its promising role in treating hereditary angioedema (HAE). The data reveal a maintained 93% reduction in HAE attacks and a median onset of symptom relief of approximately 1.1 hours for on-demand treatment. The findings support deucrictibant as a potentially preferred therapy due to its favorable safety and tolerability profile. Ongoing clinical studies aim to further validate these results and reinforce deucrictibant's position in HAE management.
Read more →PHVS▲ +10.3%on this news· ran to +24% by day 3
Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
Pharvaris has announced the upcoming initiation of the pivotal Phase 3 study, CHAPTER-3, for deucrictibant, aimed at preventing hereditary angioedema (HAE) attacks. The company is expanding its development program to include acquired angioedema (AAE-C1INH). New data presented suggests that deucrictibant could address unmet needs with its oral administration, showing potential efficacy and favorable tolerability. A conference call is scheduled to further discuss these developments.
Read more →PHVS▲ +10.3%on this news· ran to +24% by day 3
Pharvaris Presents Data at the Bradykinin Symposium 2024
Pharvaris presented significant data on its bradykinin B2 receptor antagonist, deucrictibant, at the 7th Bradykinin Symposium. The findings indicate that deucrictibant is both safe and effective in preventing hereditary angioedema (HAE) attacks, with long-term studies showing excellent patient outcomes and minimal side effects. Key results included a consistent reduction in attack rates and improved patient quality of life. These results bolster the case for deucrictibant's potential as a preferred prophylactic therapy for HAE.
Read more →PHVS▼ -7.5%on this news
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update • Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of deucrictibant; global
Pharvaris reported its second quarter financial results for 2024, highlighting its strong cash position of $344 million and continued progress in its clinical studies for deucrictibant, aimed at treating hereditary angioedema (HAE). The company has gained alignment with regulatory agencies, which is a significant milestone for its Phase 3 studies. Enrollment in the RAPIDe-3 study is moving forward as planned, and they plan to initiate additional pivotal studies soon. However, the company's R&D expenses have increased significantly, leading to a net loss for the quarter.
Read more →PHVS▼ -5.3%on this news
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses • Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours • High trea
Pharvaris has highlighted the promising properties of its drug, deucrictibant, in recent presentations at prominent congresses. The drug demonstrated a 78.6% symptom resolution rate within 24 hours for HAE attacks. Additionally, the treatment satisfaction among participants is reportedly higher compared to placebo, indicating its potential effectiveness. Pharvaris continues to explore further clinical studies to expand the understanding of deucrictibant's long-term safety and efficacy profiles.
Read more →PHVSPharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
Pharvaris, a biopharmaceutical company focused on hereditary angioedema (HAE), has announced the acceptance of abstracts for upcoming presentations at three major congresses. These include the IDDST 2024 in Japan, the EAC 2024 in Florida, and the EAACI Congress 2024 in Spain. The presentations will cover various aspects of their lead candidate, Deucrictibant, including its pharmacological profile and efficacy in treating HAE attacks. This visibility at key industry events highlights the company's ongoing dedication to developing innovative treatments for rare diseases.
Read more →PHVS▼ -7.8%on this newsshared move
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update • RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, currently enrolling  
Pharvaris reported its first quarter 2024 financial results, highlighting its ongoing pivotal Phase 3 study of deucrictibant for HAE treatment, which is currently enrolling participants. The company is executing its plans from a financially strong position, with $368 million in cash reserves. Furthermore, an End-of-Phase 2 meeting with the FDA is set to discuss the development plan for the prophylactic use of deucrictibant. However, the company also reported a significant loss for the quarter and noted the resignation of its Chief Legal Officer, which may impact operations.
Read more →PHVSPharvaris Appoints David Nassif, J.D., as Chief Financial Officer
Pharvaris has appointed David Nassif, J.D., as Chief Financial Officer, effective April 15, 2024. Nassif brings over 30 years of financial management experience and will focus on refining the company's corporate financial strategy. His expertise aims to enhance investor relations and support the growth of Pharvaris's promising pipeline of products for treating hereditary angioedema (HAE). This leadership change is viewed as a strategic move to bolster the company's financial operations and stakeholder engagement.
Read more →PHVSPharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • RAPIDe-3, a global pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, is current
Pharvaris announced its fourth quarter and full year 2023 financial results, highlighting its ongoing global Phase 3 study RAPIDe-3 on deucrictibant for HAE treatment. The company ended the year with approximately 391 million in cash reserves, significantly up from the previous year. Additionally, deucrictibant received an Innovation Passport designation in the UK, a recognition intended to accelerate access to this treatment for patients. Despite the positive developments, Pharvaris reported a loss of 101 million for 2023, reflecting its ongoing financial challenges.
Read more →PHVSPharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Pharvaris announced that two abstracts regarding its oral bradykinin B2 receptor antagonist Deucrictibant will be presented at the CIIC Spring 2024 Conference. The conference is set to take place from April 12-13, 2024, in Arlington, TX. One presentation will cover the early-onset response to Deucrictibant, while the other will discuss the efficacy and safety of the drug as a prophylactic treatment for hereditary angioedema attacks. These presentations aim to provide valuable insights into Deucrictibant's potential benefits for patients.
Read more →PHVS▲ +6.3%on this news
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
Pharvaris has announced the initiation of the Phase 3 RAPIDe-3 clinical trial aimed at evaluating the safety and efficacy of the oral bradykinin B2 receptor antagonist, deucrictibant, for treating hereditary angioedema (HAE) attacks. The study is designed to enroll around 120 global participants and will assess multiple efficacy endpoints, including symptom relief and resolution. Data from recent congress presentations highlighted the potential of deucrictibant to address significant unmet needs in HAE management, particularly in improving patient quality of life. The company is focused on delivering innovative solutions for HAE sufferers.
Read more →PHVS▲ +5.9%on this news
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
Pharvaris (Nasdaq: PHVS) has announced the acceptance of abstracts for presentations of clinical data on their oral bradykinin B2 receptor antagonist, Deucrictibant, at two upcoming congresses. These events include the 3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA) in Milan and the 2024 HAE International Regional Conference Americas in Panama City. The data presented will cover various studies including safety, efficacy, and quality of life improvements for patients with hereditary angioedema (HAE). The company aims to provide effective alternatives for managing HAE attacks through their innovative therapeutic approach.
Read more →PHVSPharvaris to Participate in the Leerink Global Biopharma Conference 2024
Pharvaris (Nasdaq: PHVS), a clinical-stage biopharma company focused on hereditary angioedema, will participate in the upcoming Leerink Global Biopharma Conference 2024. Company representative Dr. Morgan Conn will engage in a fireside chat on March 12, 2024. The event underscores Pharvaris's commitment to developing oral bradykinin B2 receptor antagonists to provide effective treatment options for HAE. A live audio webcast of the event will be available on the company's investor relations page, allowing stakeholders to follow the discussion remotely.
Read more →PHVSPharvaris Announces Extraordinary Meeting of Shareholders Zug, Switzerland
Pharvaris has announced an extraordinary general meeting of shareholders scheduled for March 6, 2024. The meeting will cover relevant documents, which will be accessible through the company's website and the SEC's site. As a clinical-stage company, Pharvaris is developing oral bradykinin B2 receptor antagonists aimed at treating and preventing hereditary angioedema attacks, with a focus on patient safety and efficacy.
Read more →PHVS▲ +6.3%on this news
Execution Version PHARVARIS N.V. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “ Agreemen t”) is made as of
Pharvaris N.V. has entered into a registration rights agreement with General Atlantic PH B.V. This agreement outlines the obligations of the company to file and maintain a shelf registration statement for the sale of securities by the investor. The agreement provides flexibility for the investor to initiate multiple offerings and defines conditions under which the company can delay or suspend registrations.
Read more →PHVSPharvaris to Present at the WSAAI Annual Meeting 2024
Pharvaris (Nasdaq: PHVS) announced the acceptance of two abstracts for poster presentation at the WSAAI Annual Meeting 2024, focusing on their oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE). The event is scheduled to take place from February 4-8, 2024, in Koloa, Hawaii. Presentations will detail findings from the RAPIDe-1 Phase 2 trial regarding treatment efficacy and safety. The company aims to provide effective alternatives for treating HAE attacks.
Read more →PHVS▲ +6.3%on this news
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks Zug, Switzerland
Pharvaris has announced that the FDA has lifted the clinical hold on the investigational new drug application for deucrictibant, a treatment for hereditary angioedema (HAE) attacks. This decision allows Pharvaris to progress with the global development of deucrictibant, including resuming the Phase 2 CHAPTER-1 study in the U.S. Following the FDA's review of nonclinical data, Pharvaris aims to request an End-of-Phase 2 meeting to align on key elements for an anticipated Phase 3 study. The company continues to develop oral formulations intended for both acute and prophylactic treatment of HAE.
Read more →PHVSCorporate Presentation January 2024 Pioneering science for patient choice Exhibit 99.2
Pharvaris presented its corporate outlook for January 2024, highlighting advancements in treatments for hereditary angioedema (HAE), particularly through deucrictibant, a bradykinin B2 receptor antagonist. The company reported positive Phase 2 trial results and plans to commence its Phase 3 study in the near future. However, it also noted a clinical hold on trials in the U.S., which poses significant regulatory risk. Despite these challenges, Pharvaris remains optimistic about its cash position and the potential market for HAE treatments.
Read more →PHVSPharvaris Provides Business Update and Outlines 2024 Strategic Priorities
Pharvaris has provided a business update projecting strategic priorities for 2024, including the anticipated initiation of the RAPIDe-3 Phase 3 clinical trial for deucrictibant, aimed at treating hereditary angioedema (HAE) attacks. The company has submitted the results of a nonclinical rodent toxicology study to the FDA to address a clinical hold on long-term prophylaxis. Additionally, the successful completion of a $300 million offering is expected to bolster its operational capabilities for upcoming research and product infrastructure. The transition of Jochen Knolle to a strategic advisor role is expected to guide Pharvaris through crucial developmental phases.
Read more →PHVSPharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA LEN UCARE Conference 2023
Pharvaris presented promising clinical data on its investigational drug, deucrictibant, at the GA²LEN UCARE Conference 2023. The pivotal Phase 2 trial, RAPIDe-1, highlighted the drug's potential in providing rapid relief from hereditary angioedema (HAE) attacks, demonstrating significant reductions in symptom onset and reliance on rescue medication. Presentations at the conference showcased favorable analyses indicating consistency and efficacy of treatment response, thus positioning Pharvaris for future studies, including a pivotal Phase 3 trial.
Read more →PHVS▲ +18.1%on this newsshared move
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
Pharvaris announced positive top-line data from the CHAPTER-1 Phase 2 clinical study of deucrictibant for hereditary angioedema (HAE). The study demonstrated a significant 84.5% reduction in mean monthly HAE attack rates compared to a placebo. Deucrictibant has shown a favorable safety profile, being well-tolerated among participants, with no serious adverse effects reported. This data supports the potential of deucrictibant to provide effective prophylactic treatment for HAE patients, with plans for further data presentation in the future.
Read more →PHVS▲ +18.1%on this newsshared move
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
Pharvaris N.V. has announced the pricing of a $300 million underwritten offering of its ordinary shares and pre-funded warrants. The offering includes 11,125,000 ordinary shares priced at $24.00 each and 1,375,000 pre-funded warrants at $23.99 each. The sale is being managed by Morgan Stanley and Leerink Partners, and is expected to close on or about December 8, 2023. The funds raised will potentially support the company's clinical-stage developments in treating hereditary angioedema.
Read more →PHVSPharvaris to Present at the GA LEN UCARE Conference 2023
Pharvaris (Nasdaq: PHVS) announced its acceptance of three abstracts for presentation at the GA²LEN UCARE Conference 2023 in São Paulo, Brazil. An oral presentation on Phase 2 trial results for Deucrictibant will be given by Dr. Markus Magerl, along with two poster presentations by Dr. Danny M. Cohn and Dr. Marcus Maurer. The conference will take place from December 7-9, 2023, and Pharvaris serves as a bronze level sponsor.
Read more →PHVSDisclaimer This Presentation contains certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained
The corporate presentation from PHVS reveals significant forward-looking statements that convey risks and uncertainties, particularly regarding their clinical trials for PHVS416 and PHVS719, which are currently on hold in the U.S. due to regulatory issues with the FDA. The presentation emphasizes the unmet needs for treatments for Hereditary Angioedema (HAE), citing that approximately 100,000 people may be affected globally. Despite showing optimism for their scientific approach, the company acknowledges the various risks that could impact their financial condition and operational performance.
Read more →PHVS▼ -11.5%on this news
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
Pharvaris has appointed Stefan Abele, Ph.D., as the new Chief Technical Operations Officer. Dr. Abele brings over 20 years of experience in pharmaceutical development, which will aid Pharvaris as it moves towards late-stage clinical trials for its oral bradykinin B2 receptor antagonist, deucrictibant. This transition is pivotal for the company's efforts to commercialize treatments for hereditary angioedema. Notably, deucrictibant could provide significant improvements over existing therapies in this area.
Read more →PHVSPharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
Pharvaris presented two ePosters at the ACAAI 2023 Annual Scientific Meeting, highlighting the efficacy of PHVS416, an immediate-release formulation of deucrictibant. The phase 2 RAPIDe-1 trial showed significant reductions in symptom relief time from hereditary angioedema (HAE) attacks. Additionally, a real-world study highlighted unsatisfactory treatment experiences among HAE patients. The company aims to enhance HAE treatment satisfaction through rapid and easy-to-administer oral therapies.
Read more →PHVSPharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update • Top-line data from Phase 2 CHAPTER-1 prophylactic study anticipated by YE2023 • Participated in an End-of-Phase 2 meetin
Pharvaris reported its financial results for the third quarter of 2023, highlighting significant developments in its clinical programs. The company expects to announce top-line data from the Phase 2 CHAPTER-1 study by the end of the year. Furthermore, they anticipate initiating the global Phase 3 study, RAPIDe-3, within the first half of 2024, following productive discussions with the FDA. However, the IND for their investigational drug, deucrictibant, remains on clinical hold in the U.S., impacting their timeline.
Read more →PHVSPharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
Pharvaris, a clinical-stage biopharma company, announced that two abstracts have been accepted for ePoster presentations at the ACAAI 2023 Annual Scientific Meeting. The conference is scheduled to occur from November 9-13, 2023, in Anaheim, CA. The presented topics will focus on both the efficacy of Deucrictibant and patient satisfaction regarding on-demand treatment for hereditary angioedema (HAE). These presentations showcase Pharvaris's commitment to developing innovative therapies to address the needs of HAE patients.
Read more →PHVSPharvaris To Present at the APAAACI 2023 International Conference
Pharvaris, a clinical-stage biopharma company focused on hereditary angioedema (HAE), has announced that it will present an abstract at the APAAACI 2023 International Conference in Singapore. The presentation will feature Phase 2 results for its oral bradykinin B2 receptor antagonist, deucrictibant, aimed at treating HAE attacks. The conference will take place from October 23-26, 2023, with the presentation scheduled for October 23 at 11:20 a.m. SGT. Following the presentation, the slides will be available on the Pharvaris investor website.
Read more →PHVSPharvaris To Present at the CIIC Fall 2023 Conference
Pharvaris (Nasdaq: PHVS) will present two abstracts at the CIIC Fall 2023 Conference on October 14, 2023, focusing on their oral bradykinin-B2-receptor antagonist, deucrictibant, for treating hereditary angioedema (HAE). The company's participation in the conference underscores its commitment to advancing treatment options for HAE patients. As a platinum level sponsor, Pharvaris will also have an exhibition booth at the event to engage with attendees and share further insights about their pipeline.
Read more →PHVS▲ +16.7%on this news
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
Pharvaris, a clinical-stage biotech company specializing in treatments for hereditary angioedema (HAE), will participate in the upcoming 2023 Cantor Global Healthcare Conference in New York. The event, scheduled for September 26-28, 2023, will feature a fireside chat led by Pharvaris management. This engagement highlights the company's ongoing development of novel therapeutic options aimed at effectively managing HAE attacks. Participants can access a live audio webcast of the discussion through Pharvaris' investor relations website.
Read more →PHVSPharvaris To Present at the 18th German Allergy Congress
Pharvaris (Nasdaq: PHVS) has announced the acceptance of two abstracts for ePoster presentation at the 18th German Allergy Congress, scheduled from September 14-16, 2023, in Bonn, Germany. The abstracts focus on the efficacy and safety of their oral bradykinin B2 receptor antagonist, deucrictibant (PHVS416), for treating hereditary angioedema (HAE) attacks. These findings will be presented by Emel Aygören-Pürsün, M.D., and Markus Magerl, M.D. Additionally, the abstracts will be published in the congress issue of the Allergo Journal International and Allergologie.
Read more →PHVSPharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Pharvaris, a clinical-stage biopharmaceutical company, is set to participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York from September 11-13, 2023. Morgan Conn, Ph.D., Chief Business Officer of Pharvaris, will take part in a fireside chat on September 11 at 3:35 p.m. ET. The company focuses on developing oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema (HAE) attacks, emphasizing its commitment to innovative solutions for patients.
Read more →PHVSPharvaris To Present at the 2023 HAEi Regional Conference EMEA
Pharvaris, a clinical-stage biopharmaceutical company, has announced the acceptance of three abstracts to be presented at the HAEi Regional Conference EMEA in Munich from September 1-3, 2023. The presentations will focus on the efficacy and safety of their oral bradykinin-B2-receptor antagonist, deucrictibant, in treating and preventing hereditary angioedema (HAE) attacks. Notable sessions include poster presentations and an oral presentation by their key medical staff. This participation underscores Pharvaris's commitment to advancing treatment options for patients with HAE.
Read more →PHVS▼ -6.9%on this news
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update • Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023 • Clinical hold lifte
Pharvaris reported its second quarter 2023 financial results, highlighting the completion of enrollment for the Phase 2 CHAPTER-1 study aimed at treating hereditary angioedema (HAE). The company also announced the lifting of a clinical hold on deucrictibant, allowing for the anticipated initiation of the global Phase 3 study by year-end 2023. Additionally, Pharvaris completed a $70 million private placement to bolster its research and development efforts, although it reported a loss of $21.9 million for the quarter. The company expects to announce top-line data from the CHAPTER-1 study by the end of the year.
Read more →PHVSPharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
Pharvaris (Nasdaq: PHVS) shared new clinical data related to its oral drug for hereditary angioedema (HAE) at the 2023 U.S. HAEA National Summit. The data from the RAPIDe-1 Phase 2 trial showed effective symptom relief and resolution of HAE attacks. Presentations were conducted by key medical personnel and attracted attention from the attendees. However, the company also highlighted various forward-looking statements that indicate potential risks and uncertainties associated with regulatory processes and ongoing trials.
Read more →PHVS▲ +8%on this news
MATERIAL UNITED STATES FEDERAL INCOME TAX AND DUTCH TAX CONSIDERATIONS The information presented under the caption “—Material U.S. Federal Income Tax Considerations to U.S. Holders” below is a discus
The article discusses material U.S. federal income tax and Dutch tax considerations for U.S. Holders of ordinary shares in the company. It details the potential tax implications of owning and disposing of shares, emphasizing that the information provided is general and not exhaustive. The discussion highlights the need for U.S. Holders to consult their tax advisers due to varying personal circumstances and potential complexities in tax laws. Additionally, the company does not expect to distribute dividends in the near future, which could affect tax responsibilities.
Read more →PHVS▲ +27.8%on this news· ran to +38% by day 1shared move
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE Zug, Switzerland
Pharvaris announced that the FDA has lifted the clinical hold on their investigational new drug application for deucrictibant, intended for on-demand treatment of hereditary angioedema (HAE). This development allows the continuation of PHVS416's clinical trials in the U.S., including the resumption of the RAPIDe-2 extension study. The company is preparing for a global Phase 3 study and plans to provide key data from a 26-week nonclinical study by the end of 2023. Overall, Pharvaris aims to provide effective treatment options for HAE patients.
Read more →PHVSPharvaris Announces $70 Million Private Placement Financing
Pharvaris has announced a private placement financing of approximately $70 million through the sale of 6,951,340 ordinary shares at $10.07 each. This funding is aimed at supporting research and development for its novel oral bradykinin-B2-receptor antagonists, intended for the treatment of hereditary angioedema. The offering is expected to close on June 21, 2023, subject to customary closing conditions. Pharvaris emphasizes the importance of this financing in further advancing its clinical efforts and product discovery.
Read more →PHVSSUBSCRIPTION AGREEMENT Pharvaris N.V. Emmy Noetherweg 2 2333 BK Leiden The Netherlands Ladies and Gentlemen: Pharvaris N.V., a public company with limited liability ( naamloze vennootschap ), having its official seat in
Pharvaris N.V. has announced a subscription agreement for the issuance of ordinary shares at a price of $10.07 per share. This agreement involves several investors subscribing to an agreed number of shares, with the closing of the subscription anticipated to occur shortly. The deal outlines the company’s obligations and the conditions necessary for finalizing the transaction, including the requirement for all representations to hold true and for necessary consents to be obtained. This move indicates the company's effort to raise capital and strengthen its investment standing.
Read more →PHVSPharvaris Reports First Quarter 2023 Financial Results and Provides Business Update • Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 (immediate-release deucrictibant capsules) for the pr
Pharvaris reported its first quarter 2023 financial results, noting a cash position of $135 million. The company anticipates announcing top-line data from its CHAPTER-1 Phase 2 study of PHVS416 for HAE by the end of 2023. Despite ongoing clinical and non-clinical studies, the project remains on hold in the U.S. due to regulatory requirements. The company also highlighted increasing research and administrative expenses alongside a financial loss for the quarter.
Read more →PHVSPharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update • Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE,
Pharvaris reported its fourth quarter and full year 2022 financial results and business updates, showcasing a strong cash position of $162 million. The company anticipates the announcement of top-line data from its CHAPTER-1 Phase 2 study of PHVS416 for hereditary angioedema (HAE) in the second half of 2023, despite current clinical holds in the U.S. Additionally, the recent positive results from the RAPIDe-1 study were highlighted, demonstrating potential benefits of PHVS416. Overall, Pharvaris continues to focus on developing novel therapies for HAE with significant milestones ahead.
Read more →PHVS▼ -15.4%on this news
Disclaimer This Presentation may contain certain “forward‐looking statements” within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contai
The presentation outlines Pharvaris' focus on developing treatments for hereditary angioedema (HAE) and other bradykinin-mediated diseases, emphasizing their novel drug candidates PHVS416 and PHVS719. However, the company currently faces a clinical hold on PHA121 trials in the U.S., introducing regulatory uncertainties. The management team boasts significant expertise in the field, and the company maintains a strong financial position to support its initiatives. The global market for HAE treatments presents a substantial opportunity, though various risks, including those from pandemic impacts, persist.
Read more →PHVS▲ +8.5%on this news
Pharvaris to Present in Upcoming March Investor Conferences
Pharvaris (Nasdaq: PHVS) announced its participation in two upcoming investor conferences in March. The first event is the BioCapital Europe 2023, taking place in Amsterdam on March 9, followed by the Oppenheimer 33rd Annual Healthcare Conference, which will be hosted virtually on March 13. The company's focus is on developing oral bradykinin-B2-receptor antagonists aimed at treating hereditary angioedema attacks, illustrating its commitment to addressing rare diseases.
Read more →PHVS▼ -9.2%on this news
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
Pharvaris has announced that it will present positive Phase 2 data from its RAPIDe-1 study of PHVS416 for the on-demand treatment of hereditary angioedema (HAE) at the AAAAI Annual Meeting. The study demonstrated a significant reduction in symptoms associated with HAE attacks, showcasing PHVS416's potential as an effective oral treatment option. With favorable results across all key efficacy endpoints, the data paves the way for further development of this investigational therapy. The presentation will take place on February 26, 2023, in San Antonio, TX.
Read more →PHVSPharvaris to Present at SVB Securities Global Biopharma Conference
Pharvaris, a clinical-stage biopharmaceutical company, has announced its participation in the upcoming SVB Securities Global Biopharma Conference from February 14 to February 16, 2023. The company's management is scheduled to present on February 15 at 2:40 p.m. CEST. Pharvaris specializes in developing oral bradykinin-B2-receptor antagonists aimed at treating and preventing hereditary angioedema (HAE) attacks. The presentation will be accessible via a live audio webcast on Pharvaris’ website, with a replay available for 30 days afterward.
Read more →PHVSPharvaris Provides Regulatory, Clinical, and Corporate Updates
Pharvaris has shared recent updates concerning its clinical development programs and business outlook. The company focuses on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema. However, it faces challenges, including clinical holds on its trials in the U.S. The impact of regulatory interactions and the ongoing COVID-19 pandemic adds uncertainty to their progress.
Read more →PHVS▲ +356.6%on this news
Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacks Participated in a Type A meeting with the FDA regarding the previously announced holds on the clinical studies of PHA121 in the U.S. Top-line data from CH
Read more →PHVS▲ +356.6%on this news
RAPIDe-1 Phase 2 Top-line Data
RAPIDe-1 Phase 2 Top-line Data December 8, 2022 Disclaimer This Presentation may contain certain "forward looking statements" within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do
Read more →PHVS▲ +356.6%on this news
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Primary endpoint met, substantially reducing HAE attack symptoms All secondary endpoints met PH
Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks ZUG, Switzerland, December 8, 2022 - Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat
Read more →PHVS▼ -10.3%on this news
Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
ZUG, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced it will be presenting two in-person “ePoster
Read more →PHVS▼ -9.7%on this news· ran to -21% by day 3
Pioneering science for patient choice November 2022 EX-99.1 Disclaimer This Presentation may contain certain "forward looking statements" within the meaning of the federal securities laws that involve substantial risks a
Pioneering science for patient choice November 2022 EX-99.1 Disclaimer This Presentation may contain certain "forward looking statements" within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presenta
Read more →PHVS▼ -10.1%on this news
Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop
ZUG, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the presentation of preclinical and clinical
Read more →PHVSPharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
ZUG, Switzerland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the promotion of Annick Deschoolmeester to C
Read more →PHVSPharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium
ZUG, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today presented data supporting the development program for
Read more →PHVSPharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S. Top-line data anti
Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update Zug, Switzerland, September 12, 2022 Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE
Read more →PHVS▼ -34.3%on this news· ran to -47% by day 3
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S. Zug, Switzerland
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S. Zug, Switzerland, August 22, 2022 - Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks,
Read more →PHVSPharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference
ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced tha
Read more →PHVSPioneering science for patient choice July 2022 2022 2022 Disclaimer This Presentation may contain certain "forward looking statements" within the meaning of the federal securities laws that involve substantial risks and
Disclaimer This Presentation may contain certain "forward looking statements" within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements contained in this Presentation that do not relate to matters of historical fact should
Read more →PHVSPharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13
ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced tha
Read more →PHVS▲ +9.1%on this news
Pharvaris Participates in the Kinin 2022 Conference
ZUG, Switzerland, June 07, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced the
Read more →PHVSPharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)
ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced comp
Read more →PHVSPharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipat
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights Zug, Switzerland, May 11, 2022 - Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its
Read more →PHVSPharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer • Pharvaris' executive team further strengthened by Ms. Schmidt's deep international experience and biopharmaceutical industry tenure
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer ZUG, Switzerland, May 11, 2022 - Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in here
Read more →PHVSPharvaris to Participate in BofA Securities 2022 Healthcare Conference
ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced tha
Read more →PHVSPharvaris to Participate in Upcoming April Investor Conferences
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced th
Read more →PHVSPharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights Phase 1 pharmacokinetics study demonstrates PHVS719 well tolerated with extended-release profile supporting once-dail
Pharvaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights Zug, Switzerland, March 29, 2022 - Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks
Read more →PHVSPharvaris Announces Preclinical Pharmacological Data for Small Molecule PHA121 Published in International Immunopharmacology
ZUG, Switzerland, March 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-recep
Read more →PHVSPharvaris to Participate in Upcoming March Investor Conferences
ZUG, Switzerland, March 03, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-recep
Read more →PHVSPharvaris to Participate in 11th Annual SVB Leerink Global Healthcare Conference
ZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-recept
Read more →PHVS▼ -9.3%on this news
Pioneering science for patient choice January 2022 2022 2022 Disclaimer This Presentation may contain certain "forward looking statements" within the meaning of the federal securities laws that involve substantial risks
Disclaimer This Presentation may contain certain "forward looking statements" within the meaning of the federal securities laws that involve substantial risks and uncertainties. All statements other than statements of historical factors contained in this Presentation, including
Read more →PHVSPharvaris Announces Changes to its Board of Directors Zug, Switzerland
Pharvaris Announces Changes to its Board of Directors Zug, Switzerland, Dec. 22, 2021 Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema
Read more →PHVSPharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022 CHAPTER-
Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business Highlights Zug, Switzerland, Nov. 10, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the
Read more →PHVSPharvaris to Participate in Upcoming September Investor Conferences
ZUG, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-recep
Read more →PHVS▲ +5.1%on this news
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks expanding to US, expected to report data in 2022 CHAP
Pharvaris Reports Second Quarter 2021 Financial Results and Provides Business Highlights Zug, Switzerland, July 30, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the
Read more →PHVSPharvaris Presents Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021
ZUG, Switzerland, July 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-recept
Read more →PHVSPharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 Zug, Switzerland
Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021 Zug, Switzerland, July 1, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B
Read more →PHVSPharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop
ZUG, Switzerland, June 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-recept
Read more →PHVSPharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks proceeding HAE CHAPTER-1, Phase 2 prophylactic study o
Pharvaris Reports First Quarter 2021 Financial Results and Provides Business Highlights Zug, Switzerland, May 26, 2021 - Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the t
Read more →PHVSPharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer Industry veteran with deep commercial experience further strengthens leadership team as company advances development of multipl
Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer Zug, Switzerland, May 12, 2021 Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oral bradykinin-B2-recepto
Read more →PHVSPharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights RAPIDe-1 clinical trial enrolling, evaluating PHVS416 as an oral on-demand therapy for HAE Open IND for the prophylactic evaluation of P
Pharvaris Reports Full Year 2020 Financial Results and Provides Business Highlights Zug, Switzerland, April 29, 2021 Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of
Read more →PHVSPharvaris Announces FDA Acceptance of IND Application for Prophylactic Treatment of HAE Using PHVS416
ZUG, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-medi
Read more →PHVSPharvaris to Participate in BioCapital Europe
ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-medi
Read more →PHVSPharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-media
Read more →PHVSPharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
ZUG, Switzerland, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for th
Read more →PHVSPharvaris Announces Closing of Initial Public Offering
ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor
Read more →PHVSPharvaris Announces Pricing of Upsized Initial Public Offering
ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for
Read more →Competitive Position
How PHVS ranks across every disease it competes inCompetitive Position is a premium feature
See how PHVS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial